同時,藥明康德提到,細胞及基因療法CTDMO業務板塊(WuXi ATU)2022年將是個業務發展的轉折之年,公司預計收入增長有望超過行業增長速度...
▎藥明康德OXGENE will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene ther...